Navigation Links
Watson Acquires Specifar Pharmaceuticals
Date:5/25/2011

PARSIPPANY, N.J. and ATHENS, Greece, May 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million ($562 million) in cash and certain contingent consideration. As a result of the acquisition, Watson gains a leading generic product development company that develops and out-licenses products throughout the world.  In addition, this acquisition enhances Watson's commercial presence in key European markets by providing a portfolio of approved products.  The transaction also gives Watson a strong branded-generic commercial presence in the EUR 6 billion Greek pharmaceutical market.  Specifar's pipeline includes a generic tablet version of Nexium® (esomeprazole), which could launch in certain European markets as early as the fourth quarter of 2011. Under the terms of the acquisition agreement, Specifar's former owners could receive additional consideration based on future profits from this product.

Watson anticipates that the transaction will be immediately accretive to 2011 non-GAAP earnings.  

Specifar, with annual revenue of approximately EUR 85 million for 2010, operates two core businesses.  The Company is a third-party product developer, with approximately 400 marketing authorizations licensed to third parties for sale in 36 countries, predominantly in Europe.  Specifar has eight products currently filed in the EU and additional products in development.  The Company's development business, which operates internationally, accounts for more than 70% of total revenues.

The Specifar group is in the top five in the Greek branded-generic market, with a portfolio of more than 30 products, including internally developed and in-lice
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watson Confirms Renvela® Patent Challenge
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
6. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
7. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
8. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. Advanced Instruments Acquires D & F Control Systems Inc.
11. Circassia Acquires North American and Japanese Rights to Dopexamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
(Date:10/20/2014)... Earle Martin , Chief Executive ... Ellen Teplitzky, an experienced attorney specializing in business ... has joined the firm as Director of Legal ... NDA Partners provides legal services, including research, ... top law firms and their clients in cases ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and ... and forecast of revenue. , Browse through the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bromine market, and is ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Department of Food Science and Technology, , ... Abstract , Chromosomal ... compared to those of a standard laboratory karyotype. Qualitative analysis , ... wine strains are aneuploid , and two ...
... Contributed by Jacqueline Boultwood, Gail M. Abrahamson, and J.,S. ... Headington, Oxford,OX3 9DU, United Kingdom , ... Introduction , ... in a non-invasive manner. For,example, peripheral blood may be used as ...
, , , , back to top...
Cached Biology Technology:Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 2Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 3Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 4Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 5Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 6PFGE Analysis of Chromosomal DNA From a Single Hair Root 2
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... prairie around Alberta,s Drumheller area was once a lush ... inland sea, with loads of wetlands inhabited by dinosaurs, ... changed about 71-million-years ago, according to a new study ... at the University of Calgary. The researchers, calculations show ...
... least three servings of dairy daily are three times more ... a new University of Illinois study. "And only one ... recommended amount of dairy," said Margarita Teran-Garcia, a U of ... alarming finding means that three-fourths of the 18- to 25-year-old ...
... -- Kansas State University civil engineers are developing the ... it stronger. Their innovative ingredient: biofuel byproducts. "The ... a material to use in concrete as a partial ... civil engineering, Kabul, Afghanistan. "By using these materials we ...
Cached Biology News:Dinosaur-era climate change study suggests reasons for turtle disappearance 2College kids who don't drink milk could face serious consequences 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
KOR-1 (C-20)...
...
Biology Products: